Summit Research Peptides: the FDA Record, Dated
Updated August 25, 2026
Summit Research Peptides, of Hoover, Alabama, operating summitpeptides.shop, received FDA warning letter 695607-12102024 on December 10, 2024. The agency had reviewed the company's website and a social account in October 2024, demanded a written response within 15 working days, and posted the letter publicly on December 17, 2024. Its outcome remains unknown.
Entity record
| Entity name, as addressed | Summit Research Peptides |
|---|---|
| Address on the letter | 1678 Montgomery Hwy Ste 104-285, Hoover AL 35216 |
| Storefront | summitpeptides.shop |
| Letter number | 695607-12102024 |
| Letter date | December 10, 2024 |
| Observation window | Site review conducted October 2024 — roughly two months before issuance |
| Batch | One of four same-day letters to research-peptide sellers — see the December 2024 batch record |
Letter mechanics, from the fetched text
| Delivery | Sent by email |
|---|---|
| Response demand | Written reply within 15 working days, directed to FDAADVISORY@fda.hhs.gov |
| Escalation wording | The letter warns of "seizure and injunction" among the actions available without further notice |
| Public posting | One week after issuance; the posted copy carries a content-current date of December 17, 2024 |
| Signatory | /S/ Tina Smith, M.S., Captain, USPHS, Director, Office of Unapproved Drugs and Labeling Compliance, Office of Compliance, CDER |
Statutes cited
The letter's legal chain, identical across the batch: FDCA §201(g)(1), 21 U.S.C. 321(g)(1); §201(p), 21 U.S.C. 321(p); §301(d), 21 U.S.C. 331(d); §505(a), 21 U.S.C. 355(a); and 21 CFR 201.128, the intended-use regulation. Every legal characterization in this record is FDA's, as stated in the letter.
The evidence category this letter is known for
What sets the Summit letter apart within its batch is its use of a social property under FDA's attribution formula: the account, the letter reasons, "directs consumers to your … website to purchase" the products, so material published there counts toward intended use. On that footing the letter quotes a dated May 18, 2024 post from the company's Facebook account carrying therapeutic-outcome claims for a two-compound pairing drawn from the catalog. This index does not reproduce the claims; the category is what the record documents. The method is examined at length in the social-media evidence record, and the letter's full content — including the five compounds it names — is kept at the Summit Research Peptides letter page.
One further point the fetched text supports: a page on the site framed around preclinical study reporting for the scientific community was cited alongside everything else. The framing did not remove the material from the evidentiary record.
Outcome status: unknown
As of this page's dateline, no close-out letter or follow-on action tied to letter 695607-12102024 has been located in the public record. Whether the company responded within its 15-working-day window is likewise not documented in anything this index has captured. Both are stated here as unknown, not inferred in either direction. Summit Research Peptides also holds an entry in the vendor index.
Sources
- FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
- FDA Warning Letters index — search "Summit Research Peptides" or letter number 695607-12102024 for the original document.
- FDA Roundup, December 17, 2024 — agency summary of the four-letter batch (fda.gov).
Further reading
- 2024 enforcement timeline — where this letter sits in the year's dated sequence.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.